ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:

• H.C. Wainwright 5th Annual NASH Investor ConferenceTuesday, October 12, 20213:30 pm Eastern Time

• H.C. Wainwright Hepatitis B Virus (HBV) Virtual ConferenceWednesday, October 13, 20214:30 pm Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™).   For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Investor & Media Contacts:

Will BrownChief Financial OfficerPhone: 240-654-1450wbrown@altimmune.com